ライフサイエンスコーパス: pegylated liposomal doxorubicin

1 active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

2 pan and danicopan display poor efficacy with PEGylated liposomal doxorubicin.

3 benefits and toxicity outcomes also favored pegylated-liposomal doxorubicin.

4 ohort of patients who were then treated with pegylated-liposomal doxorubicin.

5 oup) received doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg/kg) and cardiac f

6 atients, paclitaxel, capecitabine (CAPE), or pegylated liposomal doxorubicin; (2) for taxane- and ant

7 herapy were treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interl

8 -KS were randomly assigned to receive either pegylated-liposomal doxorubicin (20 mg/m2) or the combin

9 Patients received pegylated liposomal doxorubicin 24 mg/m2 intravenously o

10 lenalidomide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), and dexameth

11 and 15) plus carboplatin (AUC 5, day 1) plus pegylated liposomal doxorubicin (30 mg/m(2), day 1) ever

12 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m(2) by body su

13 T) and 2 lines of conventional chemotherapy (pegylated liposomal doxorubicin and docetaxel) was treat

14 PLN-formulated ICLs extravasated better than PEGylated liposomal doxorubicin and fluorescent dextran

15 luated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD

16 ere randomly assigned to receive carboplatin-pegylated liposomal doxorubicin-bevacizumab (experimenta

17 Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new sta

18 ylated liposomal drugs (BNT162b2 vaccine and PEGylated liposomal doxorubicin), but not purified PEG20

19 taxane-exposed/anthracycline-naive patients, pegylated liposomal doxorubicin, CAPE, or Eribulin.

20 evidence for reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenua

21 izumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizuma

22 ge (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem me

23 also enhanced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).

24 Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceu

25 cal translation of c-JO4 in combination with PEGylated liposomal doxorubicin/Doxil for ovarian cancer

26 studied standard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt t

27 e; these drugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine

28 cal pathway, demonstrates poor efficacy with PEGylated liposomal doxorubicin, even in sera with anti-

29 In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly

30 1b investigating TILT-123, pembrolizumab and PEGylated liposomal doxorubicin in a similar patient pop

31 etermine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemc

32 Pegylated liposomal doxorubicin in combination with gemc

33 Pegylated liposomal doxorubicin is an effective treatmen

34 Pegylated-liposomal doxorubicin is more effective and le

35 Pegylated-liposomal doxorubicin offers a new alternative

36 Among 133 patients randomized to receive pegylated-liposomal doxorubicin, one achieved a complete

37 In advanced-stage KS, chemotherapy with pegylated liposomal doxorubicin or paclitaxel is the mos

38 pegol versus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinu

39 al body weight) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan).

40 ce of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine

41 d dose-limiting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD).

42 II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD

43 t results of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD

44 We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defin

45 icacy and safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with p

46 red anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention

47 parative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient po

48 e II inhibitors, doxorubicin, etoposide, and pegylated liposomal doxorubicin (PLD) in vivo, utilizing

49 Currently, pegylated liposomal doxorubicin (PLD) is a standard of c

50 the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib wi

51 a multicenter phase III study that compared pegylated liposomal doxorubicin (PLD) to the BV combinat

52 Since pegylated liposomal doxorubicin (PLD) was the most preva

53 the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD a

54 el, phase II trial evaluated the bortezomib, pegylated liposomal doxorubicin (PLD), and dexamethasone

55 S-associated Kaposi sarcoma is paclitaxel or pegylated liposomal doxorubicin (PLD); neither is routin

56 In the healthy mouse, non-pegylated liposomal doxorubicin showed a minimal and non

57 ilar basophil activation could be induced by PEGylated liposomal doxorubicin, suggesting that PEGylat

58 oice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine,

59 cted chemotherapy (once weekly paclitaxel or pegylated liposomal doxorubicin) until disease progressi

60 After investigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or t

61 acy and toxicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combinati